| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | BZLF1 |
| Uniprot No | P03206 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-245aa |
| 氨基酸序列 | MMDPNSTSEDVKFTPDPYQVPFVQAFDQATRVYQDLGGPSQAPLPCVLWPVLPEPLPQGQLTAYHVSTAPTGSWFSAPQPAPENAYQAYAAPQLFPVSDITQNQQTNQAGGEAPQPGDNSTVQTAAAVVFACPGANQGQQLADIGVPQPAPVAAPARRTRKPQQPESLEECDSELEIKRYKNRVASRKCRAKFKQLLQHYREVAAAKSSENDRLRLLLKQMCPSLDVDSIIPRTPDVLHEDLLNF |
| 预测分子量 | 42. 9kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于BZLF1重组蛋白的参考文献及其摘要概述：
---
1. **文献名称**：*"Recombinant BZLF1 protein of Epstein-Barr virus induces apoptosis through the mitochondrial pathway"*
**作者**：Hagemeier et al.
**摘要**：研究利用重组BZLF1蛋白在体外模型中证明其通过激活线粒体途径诱导宿主细胞凋亡，揭示了BZLF1在EB病毒裂解期对宿主细胞死亡的调控机制。
---
2. **文献名称**：*"Structural basis of DNA recognition by the EBV transactivator BZLF1"*
**作者**：Petosa et al.
**摘要**：通过X射线晶体学解析重组BZLF1蛋白的DNA结合结构域，阐明其特异性识别病毒早期基因启动子序列的分子机制，为靶向药物设计提供结构基础。
---
3. **文献名称**：*"Recombinant BZLF1 protein triggers lytic reactivation of Epstein-Barr virus in latently infected B cells"*
**作者**：Feederle et al.
**摘要**：实验证明重组BZLF1蛋白可直接激活潜伏EB病毒的裂解周期，并揭示其在病毒再激活中的关键转录调控功能，为抗病毒治疗提供新靶点。
---
如需更多文献或具体细节，可进一步补充说明!
**Background of BZLF1 Recombinant Protein**
The BZLF1 protein, encoded by the immediate-early gene *BZLF1* (also known as *Zta* or *ZEBRA*), is a key regulatory protein of Epstein-Barr virus (EBV), a gammaherpesvirus linked to several human malignancies and infectious diseases. BZLF1 serves as a transcriptional activator that triggers the switch from latent to lytic viral replication by binding to specific DNA sequences (ZREs) in EBV promoters. Its expression is tightly regulated during latency but becomes rapidly induced in response to cellular stress, chemical agents, or immune signals, initiating the lytic cycle cascade.
Recombinant BZLF1 protein is produced through genetic engineering, typically by expressing the *BZLF1* gene in bacterial or eukaryotic systems followed by purification. The protein contains functional domains critical for its activity, including a DNA-binding domain, a dimerization domain, and transactivation regions. Researchers utilize recombinant BZLF1 to study its structure-function relationships, interaction with host cell factors (e.g., NF-κB, p53), and mechanisms underlying viral reactivation. It is also employed in assays to screen antiviral compounds or to develop diagnostic tools for EBV-associated diseases.
Studies involving BZLF1 recombinant protein have advanced understanding of EBV pathogenesis, host-virus interactions, and lytic cycle regulation. Additionally, its role in immune evasion and oncogenesis makes it a potential target for therapeutic interventions, such as vaccines or lytic induction therapies to eliminate latent EBV reservoirs in cancer cells.
×
